Physician profile
Faina Kogan
NPI 1144374380
$6,500.19
in general payments reported to CMS, 2019-2025
44 companies · $822 in 2025
The $822 reported for 2025 was more than what 86% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $657 · 2021: $1,424 · 2022: $1,025 · 2023: $645 · 2024: $803 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,873.47 | 2019-2025 | |
| Amgen INC. | $735.10 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $570.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $438.31 | 2019-2025 | Shingrix |
| Lilly USA, LLC | $393.56 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $299.15 | 2019-2021 | |
| Horizon Therapeutics Plc | $208.66 | 2019-2022 | |
| Novo Nordisk INC | $200.06 | 2019-2022 | |
| Pfizer INC. | $190.78 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $160.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.00 | 2019-2022 | |
| Allergan, INC. | $100.26 | 2019-2020 | |
| Mylan Specialty L.P. | $96.85 | 2020-2023 | Yupelri |
| Insmed, INC. | $88.10 | 2022-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $82.17 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faina Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.